Jazz Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
For the full year, revenue was USD 3,834.2 million compared to USD 3,659.37 million a year ago. Net income was USD 414.83 million compared to net loss of USD 224.06 million a year ago. Basic earnings per share from continuing operations was USD 6.55 compared to basic loss per share from continuing operations of USD 3.58 a year ago. Diluted earnings per share from continuing operations was USD 6.1 compared to diluted loss per share from continuing operations of USD 3.58 a year ago.